172 results on '"Leheurteur M"'
Search Results
2. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
3. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
4. 20P Deciphering tumor microenvironment heterogeneity between primary tumor and metastases in high grade serous ovarian cancer (HGSC) to predict response to immunotherapy (IT): Analyses from the NeoPembrOv/GINECO phase II trial
5. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
6. 217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort
7. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours
8. 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database
9. 282P Impact of pembrolizumab on ovarian function in young triple negative breast cancer patients treated with chemo-immunotherapy
10. 238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
11. Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients
12. Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188]
13. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
14. 1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO
15. 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers
16. 1672P Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)
17. 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
18. 102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database
19. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
20. Neoadjuvant endocrine therapy in breast cancer
21. Prise en charge du cancer du sein des personnes âgées vulnérables
22. 265P Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
23. Facteurs pronostiques de la survie sans progression chez les patientes atteintes d’un cancer du sein métastatique de type RH+/HER2- avant l’avènement des inhibiteurs CDK dans la cohorte nationale ESME
24. Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients
25. Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: A GINECO study
26. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
27. Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
28. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
29. Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
30. Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
31. Shared decision of adjuvant chemotherapy including a genomic test: 1 year patients reported outcomes in a multicenter, national clinical trial (UCBG-2-14)
32. Abstract P6-14-06: Oral etoposide (VP-16) in heavily pre-treated metastatic breast cancer: A multicenter national observational study
33. Abstract P6-14-02: Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program
34. Abstract P6-08-10: Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
35. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
36. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis
37. Abstract P2-05-10: UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk
38. 1817P - Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients
39. 1037P - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: A GINECO study
40. Influence of adjuvant chemotherapy on anti-müllerian hormone (AMH) level in patients younger than 35 years treated for an early breast cancer (EBC)
41. Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
42. Corrections to “REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours”
43. 294PD_PR - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
44. 242P - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
45. 6 - Shared decision of adjuvant chemotherapy including a genomic test: 1 year patients reported outcomes in a multicenter, national clinical trial (UCBG-2-14)
46. Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients
47. 280P - FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis
48. 265P - Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
49. Feasibility of adjuvant chemotherapy in breast cancer women over 70years after comprehensive geriatric assessment (CGA)
50. Port Catheter Versus Peripherally Inserted Central Catheter in Post-Operative Chemotherapy for Early Breast Cancer: a Retrospective Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.